- Home
- IMUX vs PNI Comparison
IMUX vs PNI Comparison
Compare IMUX & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- PNI
- Stock Information
- Founded
- IMUX 2016
- PNI 2002
- Country
- IMUX United States
- PNI United States
- Employees
- IMUX N/A
- PNI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- PNI Trusts Except Educational Religious and Charitable
- Sector
- IMUX Health Care
- PNI Finance
- Exchange
- IMUX Nasdaq
- PNI Nasdaq
- Market Cap
- IMUX 92.2M
- PNI 78.4M
- IPO Year
- IMUX N/A
- PNI N/A
- Fundamental
- Price
- IMUX $0.76
- PNI $6.97
- Analyst Decision
- IMUX Strong Buy
- PNI
- Analyst Count
- IMUX 5
- PNI 0
- Target Price
- IMUX $6.00
- PNI N/A
- AVG Volume (30 Days)
- IMUX 1.3M
- PNI 26.4K
- Earning Date
- IMUX 11-13-2025
- PNI 01-01-0001
- Dividend Yield
- IMUX N/A
- PNI 4.76%
- EPS Growth
- IMUX N/A
- PNI N/A
- EPS
- IMUX N/A
- PNI N/A
- Revenue
- IMUX N/A
- PNI N/A
- Revenue This Year
- IMUX N/A
- PNI N/A
- Revenue Next Year
- IMUX N/A
- PNI N/A
- P/E Ratio
- IMUX N/A
- PNI N/A
- Revenue Growth
- IMUX N/A
- PNI N/A
- 52 Week Low
- IMUX $0.56
- PNI $6.03
- 52 Week High
- IMUX $1.42
- PNI $7.89
- Technical
- Relative Strength Index (RSI)
- IMUX 47.49
- PNI 46.14
- Support Level
- IMUX $0.67
- PNI $6.93
- Resistance Level
- IMUX $0.79
- PNI $7.01
- Average True Range (ATR)
- IMUX 0.05
- PNI 0.05
- MACD
- IMUX 0.00
- PNI -0.01
- Stochastic Oscillator
- IMUX 64.28
- PNI 33.33
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.